GMEDHealthcare · Medical DevicesThe 15 Wall Street analysts covering Globus Medical, Inc. hold a median 12-month price target of $100 — +31.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Globus Medical, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (96): The business earns solid, repeatable profits on what it owns.
Accruals (56): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (15): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on GMED, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +31.0% from it.
Of the 20 most recent actions, 0 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | RBC Capital | Maintains | Outperform | $115 → $85 |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | — |
| 7 Aug 2026 | Wells Fargo | Maintains | Overweight | $103 → $99 |
| 28 July 2026 | UBS | Initiates | Neutral | — |
| 28 July 2026 | UBS | Initiates | Neutral | $82 |
| 16 July 2026 | Truist Securities | Maintains | Buy | $115 → $100 |
| 16 July 2026 | Truist Securities | Maintains | Buy | — |
| 13 July 2026 | RBC Capital | Maintains | Outperform | $120 → $115 |
| 13 July 2026 | RBC Capital | Maintains | Outperform | — |
| 9 July 2026 | BMO Capital | Initiates | Outperform | — |
| 8 July 2026 | Stifel | Maintains | Hold | $95 → $80 |
| 8 July 2026 | Stifel | Maintains | Hold | — |
| 15 June 2026 | Piper Sandler | Maintains | Overweight | — |
| 8 May 2026 | Needham | Maintains | Buy | — |
| 8 May 2026 | RBC Capital | Maintains | Outperform | — |
| 8 May 2026 | Wells Fargo | Maintains | Overweight | — |
| 26 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 25 Feb 2026 | Barclays | Maintains | Overweight | — |
| 25 Feb 2026 | Needham | Maintains | Buy | — |
| 30 Jan 2026 | Needham | Upgrade | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GMED appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Globus Medical, Inc. returned +31.4% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 38% of US stocks
Cheaper than 36% of US stocks
Cheaper than 41% of US stocks
Cheaper than 39% of US stocks
Higher than 41% of US stocks
Higher than 18% of US stocks
Higher than 82% of US stocks
Higher than 84% of US stocks
Higher than 80% of US stocks
Higher than 68% of US stocks
Higher than 90% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Globus Medical, Inc. has a market value of $10.2B and an enterprise value of $9.8B.
Revenue in the twelve months to 30 June 2026: $3.1B. The latest quarter grew 5.9% year on year.
Net income over the same four quarters: $535.4M, a 17.0% net margin.
Diluted earnings per share, trailing twelve months: $3.91.
Free cash flow in the twelve months to 30 June 2026: $745.8M.
Globus Medical, Inc. spent $221.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 19.6×; forward P/E: 14.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Globus Medical, Inc. employs 6,000 people — $524K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Globus Medical, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Globus Medical announced it will showcase SCRIPT™ patient-specific implants and a new XLIF™ prone procedural solution at the 41st Annual North American Spine Society Meeting, held in San Antonio from October 14–17, 2026.
Why it matters — The announcement highlights GMED’s latest spine innovations at a major industry meeting.
Globus Medical said it will release financial results for the third quarter ended September 30, 2026, after market close on November 5, 2026. The release will be available on the company's investor website.
Why it matters — GMED watchers can note the scheduled date for the company's quarterly results.
Zacks Investment Research says Globus Medical is gaining musculoskeletal share, citing strong spine and trauma growth. It also points to product innovation and a debt-free balance sheet.
Why it matters — These factors are relevant to GMED watchers assessing the company’s growth and financial position.
Zacks Investment Research published an Industry Outlook article highlighting Globus Medical, Intuitive Surgical and Thermo Fisher Scientific. The piece includes Globus Medical among the companies featured in this industry analysis.
Why it matters — GMED watchers would care because the article places the company within a broader medical technology industry context, offering insight into sector conditions that could affect it.
Zacks Investment Research has identified Globus Medical (GMED) as a strong value stock using its Style Scores system, which helps investors find top-rated stocks based on investing style.
Why it matters — This signals that GMED is currently ranked favorably on value metrics, which could be relevant to investors tracking the stock's valuation.
The 15 Wall Street analysts covering Globus Medical, Inc. have a median 12-month price target of $100, with estimates ranging from $84 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 15 analysts covering Globus Medical, Inc., 10 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Globus Medical, Inc. 96 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Globus Medical, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).
No one can know that. What the data says: the median 12-month target from 15 analysts implies +31.0% from the last close, and Ticker Nerd's factor model ranks Globus Medical, Inc. 96 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Globus Medical, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GMED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $84 to $125 over the next 12 months.
Globus Medical, Inc. returned +31.4% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Globus Medical Inc. Class A Common Stock represents ownership in Globus Medical, a medical device company focused on musculoskeletal care.
The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Globus Medical to Showcase SCRIPT™ Patient-Specific Implants and New XLIF™ Prone Procedural Solution at NASS 2026". Globus Medical announced it will showcase SCRIPT™ patient-specific implants and a new XLIF™ prone procedural solution at the 41st Annual North American Spine Society Meeting, held in San Antonio from October 14–17, 2026.
Globus Medical Inc. Class A Common Stock represents ownership in Globus Medical, a medical device company focused on musculoskeletal care. The company develops and commercializes products for spine and orthopaedic applications, including implant systems, surgical instruments, and enabling technologies used in hospitals, physician practices, and surgical centers. Its portfolio supports procedures for spinal disorders, bone healing, and other complex musculoskeletal conditions, making it a significant supplier in the healthcare equipment market. Globus Medical also provides integrated solutions that combine devices, instrumentation, and technology to support surgical workflows and patient treatment. Headquartered in Audubon, Pennsylvania, Globus Medical serves healthcare providers in the United States and internationally.
CEO Mr. Keith W. Pfeil · 6,000 employees · United States · https://www.globusmedical.com
